Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies by Winkelhorst, D. et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ierr20
Download by: [Universiteit Leiden / LUMC] Date: 23 August 2017, At: 01:02
Expert Review of Hematology
ISSN: 1747-4086 (Print) 1747-4094 (Online) Journal homepage: http://www.tandfonline.com/loi/ierr20
Fetal and neonatal alloimmune
thrombocytopenia: evidence based antenatal and
postnatal management strategies
Dian Winkelhorst , Dick Oepkes & Enrico Lopriore
To cite this article: Dian Winkelhorst , Dick Oepkes & Enrico Lopriore (2017) Fetal and neonatal
alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies,
Expert Review of Hematology, 10:8, 729-737, DOI: 10.1080/17474086.2017.1346471
To link to this article:  http://dx.doi.org/10.1080/17474086.2017.1346471
© 2017 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group
Accepted author version posted online: 23
Jun 2017.
Published online: 29 Jun 2017.
Submit your article to this journal 
Article views: 259
View related articles 
View Crossmark data
REVIEW
Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and
postnatal management strategies
Dian Winkelhorst a,b, Dick Oepkesa and Enrico Lopriorec
aDivision of Fetal Therapy, Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands; bDepartment Immunohematology
Experimental, Sanquin, Amsterdam, The Netherlands; cDivision of Neonatology, Department of Pediatrics, Leiden University Medical Center,
Leiden, The Netherlands
ABSTRACT
Introduction: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a relatively rare but poten-
tially lethal disease, leading to severe bleeding complications in 1 in 11.000 newborns. It is the leading
cause of thrombocytopenia in healthy term-born neonates.
Areas covered: This review summarizes the antenatal as well as postnatal treatment, thus creating a
complete overview of all possible management strategies for FNAIT.
Expert commentary: The optimal antenatal therapy in order to prevent bleeding complications in
pregnancies complicated by FNAIT is non-invasive treatment with weekly intravenous immunoglobulin
(IVIG). Based on risk stratification, weekly doses of IVIG of 0.5 or 1.0g/kg should be administered started
early in the second in high risk cases or at the end of the second trimester in low risk cases. The optimal
postnatal treatment depends on the platelet count and the clinical condition of the newborn. Prompt
administration of compatible platelet transfusion is the first treatment of choice in case of severe
thrombocytopenia or active bleeding. In case matched platelets are not directly available, random
platelets can also be administered initially to gain time until matched platelets are available. In case of
persistent thrombocytopenia despite transfusions, IVIG 1.0–2.0g/kg can be administered.
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Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is
one of the leading causes of thrombocytopenia in otherwise
healthy newborns [1,2]. FNAIT results from maternal alloanti-
body formation as a result of exposure to the incompatible,
paternally derived human platelet antigen (HPA) on fetal pla-
telets. When these HPA-alloantibodies enter the fetal circula-
tion after passing the placenta through FcRn-mediated
transport, they can destruct fetal platelets as well as damage
endothelial cells, which may result in bleeding complications
[3,4]. These bleedings can vary from minor skin manifestations
to severe intracranial hemorrhages (ICHs) or even perinatal
death [5,6]. In absence of population-based screening for
FNAIT, cases are predominantly diagnosed in case of symp-
toms. Therefore, the clinical challenge lies in treating the
thrombocytopenic neonate with newly diagnosed FNAIT and,
in potential subsequent pregnancies, preventing the occur-
rence of such bleeding complications through antenatal ther-
apy. Fortunately, these severe hemorrhages are rare
complications of FNAIT, estimated to strike in 1 in 11,000
newborns [7]. Therefore, little evidence is available to support
the choice for or the abandoning of specific treatment. In the
absence of international guidelines and large trials comparing
different strategies of treatment, most western countries and
centers base their guidelines on low levels of evidence includ-
ing clinical experience, small observational cohorts, and expert
opinions. For the antenatal management, important progress
was made over the last couple of years to generate more
substantial evidence as ground for clinical recommendations.
Next to an increase in observational cohort descriptions, both
retrospective and prospective, attempts have also been made
for randomized trials. These trials, however, are hampered by
lack of an adequate control group (placebo or no treatment)
[8–10]. In addition, most studies have a small sample size and
therefore lack power for drawing firm conclusions on the
occurrence of an ICH or perinatal death. Furthermore, without
any international consensus, management strategies applied
are highly heterogeneous, which makes it difficult to combine
the data of primary studies. For neonatal management in
FNAIT, evidence is even more scarce. No randomized studies
have been performed and just a handful of observational
studies have been executed, all retrospectively analyzing a
small number of newborns treated at various centers with
various management strategies. This review aims to provide
an overview with all relevant literature and summarizes the
evidence for both antenatal and postnatal management stra-
tegies in FNAIT.
2. Diagnosis
In the absence of population-based screening, suspicion of
FNAIT predominantly arises in case of bleeding problems.
Occasionally, these bleedings are detected or suspected during
fetal life, in case of ultrasound abnormalities, especially in the
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fetal brain. More commonly suspicion of FNAIT emerges after
birth and results from neonatal bleeding problems or a chance
finding of an early-onset isolated severe thrombocytopenia.
Additionally, FNAIT is sporadically diagnosed in case of a diag-
nostic work-up because of a sister or another family member
with a pregnancy complicated by FNAIT. When FNAIT is sus-
pected, or in case of a family member with FNAIT, diagnostic
work-up should ideally include HPA genotyping of mother,
father, and child to establish possible HPA incompatibilities, as
well as serological testing (maternal–paternal serum crossmatch,
and a maternal platelet antibody screening) [11–15]. A serologi-
cal FNAIT diagnosis is confirmed in case of a maternal–neonatal
or maternal–paternal incompatibility combined with the pre-
sence of specific anti-HPA in maternal serum. If, in case of suspi-
cion due to an affected family member, after the HPA-typing, the
pregnant women turns out to be HPA-1a negative, the HPA-1a
type of father and, in case of paternal heterozygosity, conse-
quently fetus can be determined as described below. In case of
HPA-1a incompatibility between mother and fetus without anti-
HPA-1a present, the alloantibody screening should be repeated
every 2–4 weeks.
Adequate diagnosis does not only contribute to adequate
management in the index cases, but is just as important for
taking adequate measures in subsequent pregnancies to pre-
vent bleeding complications.
3. Antenatal management
Antenatal management is usually applied in subsequent preg-
nancies after the birth of a first affected child. However, in case
of diagnosis during pregnancy, the same management strate-
gies are applied to index cases as well. The only exception is
the gestational age to start treatment, which is at moment of
diagnosis for index pregnancies. Antenatal management in
subsequent pregnancies starts after conception with counsel-
ing, monitoring, and risk stratification. Also, depending on the
HPA-alloimmunization that is involved, a prediction can be
made on the severity of the disease. It is usually thought
that, for example, HPA-15b or HPA-1b antibodies will cause
less severe disease than, for example, HPA-3a or HPA-1a
alloantibodies. However, in lack of sufficient evidence or lit-
erature to support these assumptions, no recommendations or
guidelines exist to advice on different antenatal management
strategies with different types of alloimmunizations.
3.1. Monitoring and risk stratification
First it has to be determined whether or not the pregnancy is
incompatible and actually at risk for FNAIT, depending on
paternal genotype for the causing antigen. When the father
is homozygous, every consecutive pregnancy is incompatible
and therefore the fetus is at risk. When the father is hetero-
zygous, fetal genotyping has to be performed. In case of HPA-
1a alloimmunization, this can be tested using the cell free fetal
DNA in maternal plasma [16]. Additionally, using parallel
sequencing, fetal HPA-3, HPA-5, HPA-15 might be determined,
as suggested by Wienzek-Lischka et al. [17]. In other cases, an
amniocentesis has to be performed to obtain fetal DNA.
When established that the pregnancy is incompatible for
the HPA-alloantibody present in the maternal serum, the fetal
brain should be closely monitored through serial ultrasound.
At this stage, ideally a noninvasive diagnostic tool should be
used to evaluate and monitor fetal disease severity and pre-
dict the occurrence of hemorrhages. For this purpose, some
centers monitor alloantibody titers by titration and quantifica-
tion, although mostly still in a research setting. While high
anti-HPA-1a levels correlate with more severe disease, preg-
nancies with barely detectable antibody levels and a severely
affected fetus or neonate have been described as well [18]. No
reliable cut-off values to guide individual management have
been established thus far. Therefore, its use in predicting the
occurrence of fetal/neonatal bleeding is somewhat contradic-
tory [18–20]. Several other mechanisms and markers are being
studied extensively in order to enable us to predict the fetal
and neonatal disease severity during pregnancy. For example,
the glycosylation pattern of the Fc-part of the anti-HPA alloan-
tibodies (e.g. fucosylation and galactosylation) is reported to
correlate with neonatal platelet counts as well as disease
severity [21,22]. Also, cord blood CRP levels are linked to
disease severity as well [23]. Also, the HLA-DRB3*01:01 allele,
which is associated with a higher risk of alloimmunization in
case of a HPA-1a incompatible pregnancy, is thoroughly
assessed for this reason and it has been shown that this allele
and other HLA alleles have no additional value as a predictor
of the disease severity or response to IVIG [24,25].
Another great new insight in understanding the occurrence
of ICH in FNAIT is the interaction between anti-HPA-1a alloanti-
bodies and endothelial cells. Since integrin β3 that carries the
HPA-1a epitope is also present on endothelial cells (in complex
with αV; αVβ3), it has been postulated that this leads to three
different subtypes of anti-HPA-1a [26]. The first type is not
complex-specific and will bind to β3, irrespective of its complex;
the second subtype will bind to β3 only when in complex with
α2 (principally platelets); the third type will bind solely to β3
when complexed to αV (principally endothelial cells). It has
been suggested that this third type of antibody plays a key
role in the development of bleeding complications. The first
direct proof came from murine studies in both active and
passive murine models [4]. They illuminated that ICHs occurred
regardless of platelet counts and, more importantly, that HPA-
1a antibodies inhibited angiogenic signaling, induced endothe-
lial cell apoptosis, and decreased vessel density in affected
brains as well as retinas. In addition, very recently a retrospec-
tive study assessing human FNAIT sera reported the occurrence
of ICH to be related to the presence of endothelial-specific anti-
HPA1a antibodies, the anti-αVβ3 subtype [26].
In light of the lacking parameters predicting the risk of
bleeding complications in FNAIT, this yields a very promising
focus point of future research. Therefore, in the absence of
noninvasive reliable ultrasound or laboratory parameters dur-
ing pregnancy to assess which incompatible and alloimmu-
nized pregnancies are at greater risk for developing bleeding
complications, the obstetric history is used. The most reliable
predictor for the occurrence of severe bleeding complications
so far is the occurrence of an ICH in siblings [27,28]. The
recurrence rate, without the application of antenatal treat-
ment, is estimated to be as high as 79% [29]. Therefore, the




































history of a sibling that suffered from an ICH is usually used to
adjust or intensify the antenatal treatment applied [27,30,31].
Kamphuis et al. [31] used a risk stratification based on a sibling
with ICH (high risk) or no sibling with ICH (standard risk).
Pacheco et al. [27] further divided this high risk group based
on the timing of ICH, before or after 28 weeks’ gestation.
Bussel et al. [30] used the timing of ICH to intensify treatment
as well and identified a high-risk group (ICH in perinatal
period), a very high risk group (ICH between 28–36 weeks),
and an extremely high risk group (ICH before 28 weeks).
Formerly, fetal blood sampling (FBS) was used to assess fetal
platelet counts and determine disease severity. However, due
to high complication risks, this invasive (diagnostic) procedure
is now almost completely abandoned as a first-line strategy.
3.2. Antenatal treatment
Before discussing possible antenatal treatment options, it is
important to realize the true goal of antenatal treatment. In
pregnancies complicated by FNAIT, the clinically relevant goal
is to prevent bleeding complications, rather than preventing
(severe) thrombocytopenia. Even extremely low platelet
counts do not necessarily result in clinical bleeding, and
there is increasing evidence for other pathological mechan-
isms playing a key role in the development of bleeding pro-
blems in FNAIT [4,5]. Therefore, the use of platelet counts as
outcome parameter to assess the effectiveness of antenatal
management is at least debatable. When comparing different
management strategies, this should be taken into account. An
overview of all antenatal treatment strategies can be found in
Table 1 and a summary of our recommended management
strategy is shown in Figure 1.
3.2.1. Platelet transfusion
The first prenatal management strategy in FNAIT was ultra-
sound-guided FBS, followed if needed by an intrauterine pla-
telet transfusion (IUPT), was first performed by Daffos in
1983 [32].
Besides the advantage of assessing fetal status and being
able to apply immediate treatment this invasive strategy has a
lot of disadvantages and a high risk of complications. Not only
is puncturing the umbilical cord of a potentially thrombocy-
topenic fetus in FNAIT extremely dangerous. The short life
span of transfused platelets leads to the need of at least
weekly IUPTs and therefore the accumulated complication
risk per pregnancy, defined as a loss of pregnancy or emer-
gency cesarean/delivery, is as high as 11% [33]. Nowadays,
given the potential complications, only few specialized centers
still use FBS with additional IUPT in their first-line manage-
ment strategy.
3.2.2. Intravenous immunoglobulins (IVIG)
Trying to avoid applying the hazardous invasive manage-
ment with FBS and IUPT, Bussel et al. [34] were the first to
report the successful administration of IVIG in pregnancies
complicated by FNAIT, which was directly adapted from the
treatment of immune thrombocytopenia (ITP) during preg-
nancy. Immunoglobulin treatment has first been used in the
treatment of primary immunodeficiency in 1952, but over
the past decades the number of indications has been
increasing rapidly [35,36]. IVIG is a multi-donor pooled
blood product made of human IgG antibodies, which can
theoretically result in the potential to transmit blood-born
infections [37]. The most reported side effects of IVIG are
dose-related and include headaches, dizziness, or skin rash.
Rarely, renal failure, aseptic meningitis, and thrombotic com-
plications occur [38]. The use of IVIG as an antenatal treat-
ment in pregnancies complicated by FNAIT is still off-label
and long-term follow-up data of children treated with IVIG
during fetal life are currently lacking. However, a cohort
study that examined neurodevelopmental outcome of 37
children exposed to IVIG concluded that in utero exposure
to IVIG did not seem to have any clinically apparent adverse
effects in early childhood [39]. In lack of studies comparing
IVIG to an adequate control group (placebo or no treat-
ment), no conclusions can be drawn on its effect. Instead,
IVIG treatment is usually compared to invasive management
strategies or treatment with IVIG and corticosteroids. In a
recent systematic review, assessing a total of 27 studies, we
reported a 98.7% success rate in preventing ICH in pregnan-
cies treated with IVIG only [33]. This is in line with the 97.3%
reported in the previous Cochrane analysis [40].
Due to the noninvasive nature and its effectiveness equal
to FBS and IUPT, IVIG rapidly gained ground and is currently in
most centers the first line of therapy in FNAIT. IVIG was first
administered at 1.0g/kg maternal body weight per week,
Table 1. Overview antenatal and postnatal management strategies in FNAIT.
Antenatal Postnatal
Treatment Indication/Dose Benefit Risk Indication/Dose Benefit Risk
Platelet
transfusion


























In addition to random


















1 mg iv every 8 h
Benefit unclear No evidence
PLT: platelet count, ×109/L; PTx: platelet transfusion; IVIG: intravenous immunoglobulins; ICH: intracranial hemorrhage.




































which was adapted from the treatment of ITP as well. Different
strategies with regards to dose (0.5g/kg/wk or 2.0g/kg/wk)
and start of treatment have been applied since [8,30,31].
Since, the only evident risk factor for developing an ICH thus
far is the occurrence of an ICH in a sibling, it seems logical to
stratify pregnancies into two groups with two different IVIG
treatment strategies regarding dose and start.
The gestational age at start of treatment is mainly based on
the estimated onset of ICHs. The largest study describing 43
cases of ICH, reported the gestational age of onset to be less
than 28 weeks in 54% of the cases [41]. This supports starting
IVIG earlier than the (in Europe) common 28weeks’ gestation, for
example, 24 or even 20 weeks (which is common in the United
States of America). More data are needed to make a firm recom-
mendation. In women with a previous child with an ICH, IVIG is
commonly started earlier, at 16 weeks’ gestation or even earlier.
3.2.3. Corticosteroids
To reduce possible headache complaints and support its effi-
ciency, corticosteroids can be added to the IVIG treatment. This
strategy was first described by the group of Bussel et al. as well
[34]. They started with the addition of 3–5 mg/kg dexametha-
sone to IVIG treatment, but due to limited effects as well as
significant side effects such as oligohydramnios, this therapy
was stopped soon as well as the appliance a lower dose of
1.5 mg dexamethasone because it had no additional effect
compared to IVIG treatment alone [42,43]. Dexamethasone was
then replaced by prednisone, which seems to have less side
effects at a dose of 0.5 mg/kg/day. As singular treatment, it
seems that prednisone (in a dose of 0.5 mg/kg/day) is inferior
to IVIG treatment [44]. The benefit and efficacy of adding pre-
dnisone to IVIG is debated and not yet proven. The only study
reporting a significant increase in platelet count when adding
prednisone to IVIG used a self-defined and complex outcome
measure (platelet count > 25 × 109 at second sampling, or an
increase by >10 × 109 or a platelet count >40 × 109/L that was
not decreased by >10 × 109/L) [9]. All other studies comparing
IVIG treatment to a treatment with IVIG and steroids, including a
randomized controlled trial, did not find any significant differ-
ences in platelet count, ICH or mortality [8,28,30,42,43,45].
3.3. Immunoprophylaxis
Adapted from the ability of preventing RhD-associated HDFN
with the use of anti-D immunoprophylaxis during pregnancy
and after delivery, another focus of antenatal treatment can be
the prevention of alloimmunization, Studies using recombinant
anti-HPA-1a antibody, B2GΔnab [46], have shown that this treat-
ment effectively prolonged the survival of platelets up to three
times, which suggests its in vivo therapeutic potential. However,
no in vivo clinical studies assessing its efficacy and safety have
been published thus far. Another approach is the use of human
anti-HPA-1a antibodies, similar to the anti-D, that is extracted
from the plasma of immunized women. This is currently being
investigated in the PROFNAIT project [47]. No results of phase I/II
or phase III clinical trials have been published.
3.4. Mode and timing delivery
Lastly, antenatal management includes the determination of
the mode and timing of the delivery. In the largest prospective
screening study on FNAIT performed thus far, 100,448 preg-
nant women were screened for their HPA-1a type and for anti-
HPA-1a [48]. Anti-HPA-1a was found in 170 pregnancies and
Figure 1. Recommendations for antenatal management in pregnancies complicated by FNAIT.




































instead of administration of antenatal treatment, a planned,
near-term cesarean section was performed. Of these alloim-
munized 170 pregnancies, 57 neonates with severe FNAIT
were born, of which 3 suffered severe complications (ICH or
intrauterine death). These numbers were compared to 15 pre-
viously published prospective studies combined (10 severe
complications in 51 alloimmunized pregnancies). Based on
this comparison they concluded that the applied strategy of
a near-term cesarean resulted in a lower number of severe
complications. It should be taken into consideration that this
study did not describe whether or a routine ultrasound of the
neonatal brain was performed to detect ICH that 21.5% of the
neonates suffered adverse effects and were treated at the
neonatal intensive care unit and that the design of the 15
studies was highly heterogenic. Furthermore, most studies
with a high proportion of severe complications identified
their cases postnatally, based diagnostic work-up in thrombo-
cytopenic neonates instead of a antenatal.
Next to performing a cesarean as a treatment strategy,
most centers perform a planned, near-term cesarean section,
in order to reduce the risk of possible birth trauma. However,
evidence for this rationale is lacking. First, specific intrapartum
risk of bleeding has never been proven and, in a small cohort
analysis, vaginal delivery was not associated with the occur-
rence of ICH [49]. Second, in the analysis of 43 cases of ICH, no
intrapartum bleedings were detected and only 3 of 43 ICHs
were thought to have occurred after delivery [41]. Also, most
women receiving antenatal therapy are multiparous and a
nontraumatic spontaneous delivery is usually expected. So,
in women with a previous vaginal delivery, without a sibling
who suffered from ICH, a planned induction of labor can be
considered a safe strategy. Although no evidence exists to
advise on a mode of delivery in case of an in utero ICH, the
safest option possibly is a near-term CS. For all vaginal deliv-
eries, it is recommended to avoid any potential traumatic
events, such as scalp electrodes, scalp blood samplings, or
assisted vaginal delivery. Directly after delivery, cord blood
samples should be taken to rapidly assess platelet count.
4. Postnatal management
The goal of postnatal management in FNAIT is to prevent or
stop neonatal thrombocytopenic hemorrhage. As part of the
initial evaluation, newborns should be checked for skin bleed-
ing and also a cranial ultrasound examination to exclude ICH
should be performed. Laboratory evaluation should be per-
formed immediately, preferably from cord blood, to assess the
severity of the thrombocytopenia. Depending on both the
clinical presentation and the severity of the thrombocytope-
nia, the optimal treatment will be determined.
4.1. Monitoring
During the first days of life, platelet counts should be evalu-
ated daily. Because of a natural fall in neonatal platelet count
in the first week of life, it is advised to monitor neonatal
platelets at least until 5 days after birth or until there is a
sustained rise in platelet count [50,51]. The nadir platelet
count usually occurs at 36–48 h after birth. With or without
treatment, the neonate should achieve normal platelet counts
within 8–10 days.
Regardless of platelet count, all neonates with a confirmed
diagnosis should undergo cerebral imaging by ultrasound,
preferably within the first 24 h [5,52]. Most ICHs have already
occurred in utero and are therefore mostly detected on the
first days of life. However, ICH can occasionally be detected at
or after the fourth or fifth day of life as well [41]. As low
platelet counts in newborns have been proven to be asso-
ciated with severe aggressive posterior retinopathy of prema-
turity, neonatal fundus examination can be considered,
especially in neonates with severe thrombocytopenia [53].
4.2. Postnatal treatment
The best management of the neonate suffering from FNAIT
depends on the clinical condition and the severity of the throm-
bocytopenia [54]. Despite the previously mentioned lack of
evidence on postnatal management strategies, there is interna-
tional consensus that the first choice of treatment should be a
platelet transfusion, administered as quickly as possible. Other
therapies that can be applied are IVIG or corticosteroids. Table 1
displays a summary of different postnatal management strate-
gies. Also, an overview of observational studies describing neo-
natal treatment in FNAIT is given in Table 2.
4.2.1. Platelet transfusion
Platelet transfusions can be administered in case of neonatal
thrombocytopenia in either a prophylactic (nonbleeding neo-
nate) or a therapeutic setting (bleeding neonate). Of all throm-
bocytopenic neonates transfused, up to 98% were transfused
as a prophylactic measure [55]. As with every therapy and
especially prophylaxis, benefits have to outweigh the risks. In
these cases the risks of the (potential) hemorrhage should be
compared to the risks of platelet transfusions, which are the
transmission of nonbacterial infections, immunization, febrile
reactions, hemolytic reactions, allergic reactions, and transfu-
sion-related lung injury [51,56,57].
Therefore thrombocytopenic neonates should only be
transfused in case of (very) severe thrombocytopenia. Various
thresholds for (prophylactic) platelet transfusions are currently
being used, based on low level of evidence (mainly expert
opinion). Over the last decades these thresholds have gradu-
ally been lowered due to lack of evidence of a protective
effect [58]. For stable nonbleeding neonates, most centers
have set a threshold for prophylactic transfusion at 30x109/L.
However, other centers, for example, the Dutch referral hospi-
tal for FNAIT, use a lower threshold of 20 × 109/L [59]. The
threshold can be raised to 50 × 109/L in case of additional risk
factors, such as a sibling that suffered from ICH, a planned
operation, recovering from a large hemorrhage, severe pre-
maturity (<32 weeks’ gestation), low birth weight (<1000 g
within the first week of age) or a clinically instable neonate. In
the event of a bleeding neonate the threshold is usually
heightened to 50 × 109/L, or even 100 × 109/L in case of
large hemorrhages [60].
Ideally, the transfused product contains antigen-negative
platelets. In case of a subsequent pregnancy or antenatal diag-
nosis of FNAIT, the responsible alloantibody is known and




































appropriate platelets can be ordered in time. However, in index
cases, confirmation of the diagnosis can take a couple of days, so
the responsible platelet alloantibody is still unknown. In view of
poor outcome of major hemorrhages, platelet transfusions in
these neonates should not be delayed [60–62]. In these cases
ideally HPA-1bb/5aa platelets are transfused, which are antigen-
negative for 90% of the FNAIT cases [63]. When unobtainable or
not directly available, transfusion can contain either random
platelets or washed maternal platelets. Although maternal plate-
lets seem to be the superior option, because all alloantibodies in
the fetal circulation are invariably unable to interact with mater-
nal platelets, these need to be washed and irradiated, which can
destroy the platelets and makes it a time-consuming strategy. In
urgent situations, newborns can also be transfused with random
platelets. As analyzed by Kiefel et al. [60], multiple random
platelet transfusions are sufficient in increasing the platelet
count in most of the FNAIT cases and are therefore an accep-
table strategy when matched donor platelets are not available.
Despite consensus on platelet transfusion being the first
line of therapy, there is no agreement on a ‘safe’ platelet count
or an effective transfusion regime [64].
4.2.2. IVIG
In addition to being an effective antenatal treatment strategy in
preventing bleeding complications, IVIG is also applied as a
neonatal management strategy in FNAIT. Again its exact work-
ing mechanism is not quite revealed. Theories are that periph-
eral platelet destruction is inhibited through changes in Fc
receptors on platelets and macrophages, as well as through Fc
receptor-independent mechanisms [65,66]. For all indications,
neonatal treatment of IVIG is used with a dose of 1–2 g/kg,
during 2–5 consecutive days [67,68]. Based on a retrospective
cohort analysis, we know that IVIG seems to have a response
rate of approximately 65% in postnatally detected cases [67].
However, this effect takes longer than that of a platelet transfu-
sion, and the rise in platelet count takes after IVIG treatment
may take at least 24–48 h [68,69]. Therefore, IVIG should not be
applied as first-line therapy alone in treatment of thrombocyto-
penic neonates with suspected FNAIT. Furthermore, when IVIG
treatment is applied after antenatal maternal treatment with
IVIG, the beneficial effect seems to be limited compared to the
treatment with only platelet transfusions [68].
At our center, HPA-1bb/5aa platelet concentrates are avail-
able 24/7, therefore postnatal IVIG treatment is only adminis-
tered in case of persistent very severe thrombocytopenia (<20 ×
109/L) despite two previous matched platelet transfusions. In
situations where there is no direct availability of matched plate-
lets, IVIG can be added to a random transfusion in order to
optimize and prolong the effect of the transfusion [70].
4.2.3. Other (corticosteroids, exchange transfusions)
Alternative management options include corticosteroid treat-
ment and exchange transfusions. The administration of corticos-
teroids to treat thrombocytopenia, with a dose of 1 mg
methylprednisone intravenous every 8 h, was previously sug-
gested by the group of Bussel et al. [62]. However, considering
the lack of evidence and possible side effects, the use of corti-





































































































































































































































































































































































































































































































































































































































































































































































































In the previous century, exchange transfusion, which
removes a part of the harmful circulating antibodies from
the fetal circulation, was sometimes applied in very urgent
situations where no platelets were available and treatment
with IVIG would take too long [72]. This therapy is now com-
pletely abandoned due to the high risks of (bleeding) compli-
cations associated with exchange transfusions, particularly in
thrombocytopenic neonates.
5. Expert commentary
FNAIT is an important health problem that may lead to poten-
tially life-threatening disease. Evidence onmanagement of FNAIT
is limited, and with highly deviating designs in underpowered
studies, it is hard to perceive a clear overview and develop
international recommendations or clinical guidelines. However,
we think that some conclusions can still be drawn from this little
evidence. First, optimal antenatal management should be
restricted to noninvasive treatment strategies. Because of the
high complication rate per pregnancy, estimated to be as high
as 11%, FBS or IUPT should be abandoned completely, whether
applied as diagnostic or therapeutic procedure. Second, whereas
no benefit of corticosteroid treatment is proven, noninvasive,
antenatal treatment should consist of weekly IVIG infusions
only. Taking into account the dose-related side effects, the off-
label use, costs, and effectiveness as shown in small cohorts, IVIG
should be dosed as low as possible. Though the level of evidence
is weak, the effect of 0.5 g/kg/wk seems comparable to that of
1.0 g/kg/wk, when applied in standard risk pregnancies (without
a sibling that suffered ICH) [31]. We think that in these standard-
risk pregnancies the IVIG doses can be safely lowered to 0.5 g/kg/
wk, starting at a gestational age of 24 weeks. Pregnancies after a
first affected child that suffered an ICH should be considered as
high-risk pregnancies and treatment should be started earlier, at
12–16 weeks, with the regular dose of 1.0 g/kg/wk. Decision on
the mode of delivery should be primarily based on obstetric
reasons, unless an in utero ICH occurred in the current preg-
nancy. Postnatal management guidelines are based on even
weaker level of evidence, since no randomized controlled trials
(RCTs) and only a few observational cohorts have been
described. In case of confirmed or suspected FNAIT and a severe
thrombocytopenia, the cornerstone and first choice of therapy is
a platelet transfusion. Depending on the availability, a matched
platelet transfusion should be used, potentially in combination
with IVIG treatment. If matched platelets are unavailable, random
platelets can be used but the increase in platelet count will be
reduced. Threshold for transfusion can be lowered to 20 × 109/L
in nonbleeding infants and should be raised to 50 × 109/L in case
of bleeding neonates. There is need for either an RCT or a large
observational cohort analysis to optimize recommendations on
postnatal treatment of index and subsequent newborns with
FNAIT. We think that, in order to make a truly meaningful
improvement in the management of FNAIT, clinicians should
be able to prevent the index cases from occurring, through
population-based prenatal HPA-1a screening. This way it will be
possible to identify the vast majority of the index cases of FNAIT,
that is, the cases that are caused by anti-HPA-1a. Whereas HPA-
1a is the predominant cause of FNAIT and of severe heamor-
rhage in specific, HPA-1a screening will lead to the most optimal
prevention of severe bleeding complications. After detection of
anti-HPA-1a cases, prevention can be achieved through timely
pre-emptive antenatal therapy with IVIG or a possible immuno-
prophylaxis. Therefore, next to the need for increasing the level
of evidence to optimize clinical guidelines and recommenda-
tions for FNAIT treatment, antenatal as well as postnatal, there
is a lasting need for research assessing the efficacy of implemen-
tation of population-based FNAIT screening.
6. Five-year view
Given the rarity of the disease and therefore the difficulty in
generating new evidence for determining optimal postnatal
and antenatal treatment of FNAIT, more international collabora-
tion is required to develop treatment guidelines and provide
new evidence. Hopefully, in 5 years, invasive FBS and IUPT will
be completely abandoned at all centers and replaced by antena-
tal IVIG treatment. In addition, we expect the debate about
whether or not to implement prenatal screening for FNAIT will
continue. With the results of our nationwide prospective screen-
ing study (HPA-screening In Pregnancy, HIP study), we hope to
deliver the ultimate evidence to assess whether or not popula-
tion based HPA-1a screening will be cost-effective and efficient,
at least in the Netherlands. Next to tackling this unanswered
problem, we are hoping that data from this study allows us to
develop a risk-classification model. This will enable us to identify
alloimmunized pregnancies at high risk for developing a bleed-
ing complication and thus facilitate targeted antenatal
management.
Key issues
● FNAIT is one of the leading causes of thrombocytopenia in
otherwise healthy newborns
● Antenatal management used to include FBS and IUPT, but this
management strategy has gradually been abandoned due to
the potential complications and the valid alternative using IVIG.
● Antenatal management in FNAIT is nowadays mainly based
on non-invasive treatment with weekly IVIG
● Neonatal treatment is determined by severity of thrombo-
cytopenia and clinical condition
● First choice of neonatal therapy in FNAIT is a (matched)
platelet transfusion
● Postnatal treatment can be complemented with IVIG treat-
ment in case of no response to matched transfusions, or as
an addition to random transfusions when no matched pla-
telets are available.
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